Skip to main content
. 2023 Aug 31;63:102189. doi: 10.1016/j.eclinm.2023.102189

Table 3.

The incidence of adverse events in the three groups.

Placebo Group (n = 20) RAY1216 (n = 20) RAY1216 plus RTV (n = 20)
All adverse events, n (%) 8 (40%) 3 (15%) 5 (25%)
Treatment-related adverse events, n (%) 4 (20%) 0 (0%) 1 (5%)
Severe adverse events, n (%) 0 (0%) 0 (0%) 0 (0%)